PRF in Aesthetic Medicine: What the Evidence Says

How claims are graded here

Every claim on this site sits in one of four groups, and the group matters more than the wording. Established means the claim follows from evidence that is consistent and is verifiable about the material itself — that it is prepared from the patient’s own blood at the point of care, and that it forms a fibrin scaffold without an added anticoagulant, both belong here. Limited means there is real evidence but it is narrow: growth factors have been measured from the preparation in laboratory work, and the skin-quality studies are small. Emerging means the mechanism is plausible and early work points one way, but the study that would settle it has not been done. Not supported means the claim is made confidently and the evidence does not carry it. The reason for grading rather than simply reporting is that in this subject the material itself is variable, which makes the usual comparison harder than it looks. Two clinics offering platelet-rich fibrin are not necessarily offering the same substance, because the tube, the centrifuge, the spin and the interval before use all differ and none of them is standardised. A study of one preparation is a study of that preparation, and a claim that the treatment works is a claim about a material that has not been defined.

A biologic prepared at the point of care

Platelet-rich fibrin is not a licensed product. It is a biologic prepared at the point of care from the patient’s own blood and administered in the same session, and it therefore sits outside the framework that governs manufactured injectables. There is no product authorisation, no marketing authorisation and no approved indication, because there is no product to authorise: what is injected is made in the room, from the person in it, minutes before it is used. The devices involved are regulated separately. A centrifuge and the tubes used with it are regulated as laboratory equipment rather than as a medicine, and their authorisation covers separating blood rather than producing a treatment. That gap is the reason no common standard exists. A manufactured injectable arrives with a defined composition, a defined concentration and a defined set of tests, and those are conditions of its authorisation. A point-of-care biologic has none of that, so the composition depends on the protocol the clinic uses and on how consistently it follows it. Rules for blood-derived treatments also differ between jurisdictions: some regulate the preparation and administration of blood components for clinical use, others treat a same-session autologous preparation differently from a manufactured product, and some have issued guidance on how such treatments may be advertised. Where a service describes the material as approved, the useful question is what exactly is approved, because the preparation itself generally is not.

What the risks and limits actually are

The first risk is specific to this material and it is a consequence of the same property that makes it attractive. Because the preparation is made in the room from the person’s own blood, it is only as clean as the process that produced it, and blood handled outside a controlled laboratory is a medium in which bacteria grow readily. Infection introduced during preparation is the recognised risk of point-of-care biologics, and it depends on technique, on the environment and on how long the material sits before it is used rather than on the material itself. The ordinary risks of any injection also apply: bruising, swelling, discomfort and the possibility of a result the person does not like. The autologous nature of the material removes the risks of donor transmission and immune reaction, and it does not remove these. There are limits that belong to the evidence. Because the preparation is not standardised, studies describe particular protocols rather than the treatment in general, and results from one clinic’s method may not apply to another’s. The studies are small, they differ in what they measure, and few follow people long enough to show whether a change persists. A laboratory measurement of growth factor release is a real finding and it cannot be compared directly with a clinical outcome. And an important practical limit: the material is reabsorbed, so any volume effect is temporary, which is worth knowing before a person has a treatment expecting a lasting change in shape.

What else is used, and when the reversible options come first

Doing nothing is an option and it belongs first, because a treatment that carries an infection risk and produces a temporary result should have to justify itself against the alternative of leaving things alone. Where volume or shape is the goal, the treatment designed for it is a filler: a defined volume of a defined material that holds the space it occupies, and in the case of a hyaluronic acid filler one that can be dissolved if the result is unwanted. That is the comparison a fibrin preparation cannot win on volume, because the material is reabsorbed, and a service that describes it as an alternative to a filler is describing something different. Where skin quality is the goal, other options exist with their own evidence, and this review does not rank them. Where scarring or hair is the concern, established treatments exist and the fibrin preparation is an addition to them rather than a substitute. There is also a reasonable middle position: a person who wants to see how they feel about a change in their face before making one that is not easily reversed may be better served by a treatment that can be reduced or dissolved. That is not indecision; it is the sensible ordering of a decision that is difficult to take back. Which option applies is an individual clinical question, and this review does not answer it for anyone.

How this review is kept current

This subject moves on three clocks, and the fastest one is not the evidence. Supply moves quickly: kits, tubes and devices change, protocols are revised, and a clinic’s method may differ from the method described in any published study. Regulation moves more slowly and it moves differently between countries, because the rules for blood-derived treatments are not uniform and a preparation permitted in one jurisdiction may be treated another way in the next. The evidence moves slowest of all, and it is unusually hard to move, because a study describes one protocol and the next clinic uses a different one. This review is therefore dated and revisited on a short cycle, and it covers three things. The first is whether any claim has moved between the four grading groups, in either direction, because a claim can become supported as well as cease to be. The second is regulatory status, since guidance on blood-derived treatments and on advertising them is a checkable fact that readers are entitled to have current. The third is whether the evidence base has changed in kind: another small series using another protocol is a different event from a comparison against a defined alternative, and only the second can establish whether the treatment does anything that another option does not. Where this review is wrong, the correction is made to the page rather than noted elsewhere, and the date of the most recent review is shown on every page.

Related guides